BIENAIME JEAN JACQUES

Form 4 May 17, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB

if no longer

Check this box

3235-0287 Number: January 31, Expires:

subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

2005 Estimated average burden hours per

0.5

response...

5. Relationship of Reporting Person(s) to

Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

BIENAIME JEAN JACQUES			Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				Issuer (Check all applicable)			
(Last)	(First)	`	3. Date of Earliest Transaction (Month/Day/Year)			_X_ Director _X_ Officer (give	titleOt	% Owner her (specify		
C/O BIOM	IARIN		05/15/2013				below) below) Chief Executive Officer			
PHARMA	CEUTICAL INC	., 105								
DIGITAL	DRIVE									
	(Street)	4. If	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check			
			Filed(Month/Day/Year)				Applicable Line)			
			(_X_ Form filed by One Reporting Person			
NOVATO	, CA 94949						Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Table I - Non	-Derivativ	e Seci	ırities Acqı	uired, Disposed of	f, or Benefici	ally Owned	
1.Title of	2. Transaction Date	2A. Deemed	3.	4. Securit	ies Ac	equired (A)	5. Amount of	6.	7. Nature of	
Security	(Month/Day/Year)	Execution Date,		oror Dispos			Securities	Ownership	Indirect	
(Instr. 3)		any (Month/Day/Yea	Code ar) (Instr. 8)	(Instr. 3,	+ and .	3)	Beneficially Owned	Form: Direct (D)	Beneficial Ownership	
		(11101101111111111111111111111111111111	(1110111 0)				Following	or Indirect	(Instr. 4)	
					(A)		Reported	(I)		
					or		Transaction(s)	(Instr. 4)		
			Code V	Amount	(D)	Price	(Instr. 3 and 4)			
									Shares held	
Common	44								by	
Stock	05/15/2013 <u>(1)</u>	05/15/2013	M	10,000	A	\$ 12.99	30,609	I	Bienaime	
210011									Family	
									Trust (2)	
									Shares held	
C						\$			by	
Common	05/15/2013(1)	05/15/2013	S	10,000	D	68.5477	20,609	I	Bienaime	
Stock						(3)			Family	

Trust (2)

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Common Stock	05/15/2013		A	37,800	A	\$ 0 <u>(4)</u>	125,901	D	
Common Stock	05/16/2013(5)	05/16/2013 <u>(5)</u>	M	2,000	A	\$ 12.99	22,609	I	Shares held by Bienaime Family Trust((2)
Common Stock	05/16/2013(5)	05/16/2013 <u>(5)</u>	S	2,000	D	\$ 64.6535 (<u>6)</u>	20,609	I	Shares held by Bienaime Family Trust((2)
Common Stock	05/16/2013	05/16/2013	M	5,000	A	\$ 64.6535 (6)	25,609	I	Shares held by Bienaime Family Trust((2)
Common Stock	05/17/2013	05/17/2013	M	5,000	A	\$ 64.01	30,609	I	Shares held by Bienaime Family Trust (2)
Common Stock							10,000	I	Held in irrevocable trust for Guillaume Bienaime (7)
Common Stock							10,000	I	Held in irrevocable trust for Pierre Bienaime (7)
Common Stock							10,000	I	Held in irrevocable trust for Paul Bienaime (7)
Common Stock							10,000	I	Held in irrevocable trust for Marc Bienaime (7)

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

			Held in
		I	irrevocable
			trust for
Common	20,000		Aurelie
Stock	20,000		Mitsuki
			Bienaime
			and Anais
			Kimiko (7)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Securities Code Acquired (A) or (Instr. 8) Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and A Underlying So (Instr. 3 and 4	
Stock				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Option (right to buy Common Stock)	\$ 12.99	05/15/2013 <u>(1)</u>	05/15/2013	M		10,000	11/11/2006 <u>(9)</u>	05/10/2016	Common Stock
Stock Option (right to buy) Common Stock	\$ 67.81	05/15/2013		A	220,500		11/15/2013 <u>(8)</u>	05/14/2023	Common Stock
Stock Option (right to buy) Common Stock	\$ 12.99	05/16/2013 ⁽⁵⁾	05/16/2013	M		2,000	05/11/2006	11/10/2015	Common Stock
Stock Option (right to buy) Common	\$ 12.99	05/16/2013	05/16/2013	M		5,000	05/11/2006 <u>(9)</u>	11/10/2015	Common Stock

Stock

Stock Option

(right to buy) \$ 12.99 05/17/2013 05/17/2013 M 5,000 11/11/2006(8) 05/10/2016 Common Stock

Common Stock

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949

X Chief Executive Officer

Signatures

/s/ Laura Randall Woodhead,
Attorney-in-Fact
05/17/2013

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to 10b5-1 Trading plan executed on May 1, 2013.
- (2) The reporting person and his spouse act as trustees for the Bienaime Family Trust.
- The price in column 4 is weighted average price. The price actually received ranged from \$67.42 to \$70.09. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) Restricted stock units granted on May 15, 2013. Price not applicable.
- (5) Transaction made pursuant to 10b5-1 Trading plan executed on November 12, 2012.
- The price in column 4 is weighted average price. The price actually received ranged from \$63.38 to \$67.97. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (7) The reporting person's spouse is trustee of each child's trust.
- (8) Option grant vests 6/48th on November 15, 2013 and 1/48th on the 15th day of every month thereafter.
- (9) Original option grant vests 6/48th on November 11, 2006 and 1/48th on the 11th day of every month thereafter.
- (10) Reflects number of stock options outstanding after the transaction from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 4